Mendus AB (publ) (STO: IMMU)

Market Cap	465.57M
Revenue (ttm)	6.94M
Net Income (ttm)	-138.05M
Shares Out	50.36M
EPS (ttm)	-2.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,207
Open	9.40
Previous Close	9.24
Day's Range	8.81 - 9.40
52-Week Range	7.10 - 16.38
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 30
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IMMU

Financial Performance

In 2023, Mendus AB's revenue was 28.49 million, an increase of 851.15% compared to the previous year's 3.00 million. Losses were -101.62 million, -26.78% less than in 2022.